Solventum Quarterly Cash Flow Statement
NYSE: SOLVHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Solventum free cash flow
In the quarter ended Jun 30, 2026, Solventum generated $227.0 million of operating cash flow and spent $83.0 million on capital expenditures. That left free cash flow of $144.0 million, a free-cash-flow margin of 6.5% of revenue. Free cash flow was up 144.1% from the prior year's $59.0 million.
Solventum returned $288.0 million to shareholders through share repurchases, equal to 200% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Solventum cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 92.00M | 13.00M | 63.00M | 1.27B | 90.00M | 137.00M | 31.00M | 122.00M | 89.00M | 237.00M | 272.00M | 460.00M |
| Net Income growth (YoY) | +2.22% | -90.51% | +103.23% | +937.70% | +1.12% | -42.19% | -88.60% | -73.48% | -72.27% | -19.11% | — | — |
| Depreciation & Amortization | 133.00M | 135.00M | 117.00M | 121.00M | 122.00M | 129.00M | 150.00M | 133.00M | 133.00M | 139.00M | 139.00M | 144.00M |
| Stock-Based Compensation | 38.00M | 51.00M | 37.00M | 41.00M | 34.00M | 49.00M | 25.00M | 27.00M | 56.00M | 4.00M | 7.00M | 6.00M |
| Change in Working Capital | -199.00M | -43.00M | 23.00M | 45.00M | -52.00M | -17.00M | 62.00M | -30.00M | 4.00M | 141.00M | -18.00M | 22.00M |
| Operating Cash Flow | 227.00M | -189.00M | 95.00M | 76.00M | 169.00M | 29.00M | 219.00M | 169.00M | 355.00M | 442.00M | 547.00M | 493.00M |
| Capital Expenditures | -83.00M | -84.00M | -63.00M | -97.00M | -110.00M | -109.00M | -127.00M | -93.00M | -58.00M | -102.00M | -88.00M | -66.00M |
| Investing Cash Flow | -87.00M | -77.00M | -745.00M | 3.77B | -110.00M | -114.00M | -127.00M | -93.00M | -58.00M | -102.00M | -88.00M | -6.00M |
| Share Repurchases | -288.00M | -67.00M | — | — | 0 | 0 | — | — | — | — | — | — |
| Debt Issued | 0 | 46.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.30B | 0 | 0 |
| Debt Repaid | 0 | 0 | -100.00M | -2.77B | -100.00M | -100.00M | -100.00M | -200.00M | 0 | 0 | 0 | — |
| Financing Cash Flow | -300.00M | -50.00M | -115.00M | -2.69B | -110.00M | -139.00M | -104.00M | -202.00M | -396.00M | 462.00M | -306.00M | -485.00M |
| Net Change in Cash | -157.00M | -318.00M | -764.00M | 1.15B | -45.00M | -223.00M | -10.00M | -125.00M | -99.00M | 802.00M | 152.00M | 3.00M |
| Free Cash Flow | 144.00M | -273.00M | 32.00M | -21.00M | 59.00M | -80.00M | 92.00M | 76.00M | 297.00M | 340.00M | 459.00M | 427.00M |
This table shows 12 quarterly periods of Solventum's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SOLV's reporting calendar. What is a cash flow statement?